Onkologie. 2012:6(6):304-308

Treatment of invasive fungal infections

Jana Diatková1, Martina Tošková1, Iva Kocmanová2, Jiří Mayer1,4, Zdeněk Ráčil1,4
1 Interní hematologická a onkologická klinika, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice Brno
2 Oddělení klinické biochemie a hematologie, Fakultní nemocnice Brno, Katedra laboratorních metod LF MU
3 Oddělení klinické mikrobiologie, Fakultní nemocnice Brno
4 CEITEC &ndash, Středoevropský technologický institut, Masarykova univerzita, Brno

The frequency of invasive fungal infections has significantly increased with the rise in at-risk populations of patients in the last years. Management

of deep fungal infection is difficult and the morbidity and mortality of these infections are very high. New antifungal agents provide the

managment options and improve therapeutic outcomes of these infections. This article informs about the role of available antifungal agents

in the management of invasive fungal infections and reviews empirical antifungal treatmnet and the treatment of invasive aspergillus and

candida infections. Recommendations presented below are based on the resume of the Europen Conference on Infection in Leukemia (ECIL).

Keywords: invasive fungal infections, treatment, antifungals

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Diatková J, Tošková M, Kocmanová I, Mayer J, Ráčil Z. Treatment of invasive fungal infections. Onkologie. 2012;6(6):304-308.
Download citation

References

  1. Ráčil Z, Kocmanová I, Weingergerová B, et al. Léčba invazivních mykotických infekcí u onkologických nemocných. Farmakoterapie 2008; 2: 207-217.
  2. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new, ,gold standard". Clin Infect Dis 2003; 37(3): 415-425. Go to original source... Go to PubMed...
  3. Chen SC, Sorrell TC. Antifungal Agents. Med J Aust 2007; 187(7): 404-409. Go to original source... Go to PubMed...
  4. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46(2): 201-211. Go to original source... Go to PubMed...
  5. Ráčil Z, Kouba M, Winterová J, et al. Monitoring trough voriconazole plasma concentrations in hematological patients: real clinical significance? Mycoses 2012; 55: 483-492. Go to original source... Go to PubMed...
  6. Herbrecht R, Fluckiger U, Gachot B, et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. European Journal of Cancer Supplements Guidelines from the First European Conference on Infections in Leukaemia: ECIL1 2007; 5(2): 49-59. Go to original source...
  7. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408-415. Go to original source... Go to PubMed...
  8. Viscoli C, Herbrecht R, Akan H, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64(6): 1274-1281. Go to original source... Go to PubMed...
  9. Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45(7): 1227-1233. Go to original source... Go to PubMed...
  10. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Ejc Supplements 2007; 5(2): 32-42. Go to original source...
  11. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011; 46(5): 709-718. Go to original source... Go to PubMed...
  12. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989; 86(6 Pt 1): 668-672.
  13. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72(1): 101-111. Go to original source... Go to PubMed...
  14. Tamura K, Urabe A, Yoshida M, et al. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 2009; 50(1): 92-100. Go to original source... Go to PubMed...
  15. Kubiak DW, Bryar JM, McDonnell AM, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 2010; 32(4): 637-648. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.